PDCD1 and melanoma: Besides the PD1–PDL1 interaction, the monoclonal antibody, ipilimumab that can block the expression of prototypical immune checkpoint cytotoxic T lymphocyte-associated antigen 4 (CTLA4) on T cells, has been developed for the treatment of patients with advanced melanoma [4, 7, 8, 10].